LY2140023 + sodium bicarbonate

LY2140023 + sodium bicarbonate refers to the combination of LY2140023, an investigational oral prodrug developed for schizophrenia, administered together with sodium bicarbonate. LY2140023 is metabolized in the body to LY404039, a potent agonist of the metabotropic glutamate 2/3 (mGlu2/3) receptors, and is designed to modulate glutamate neurotransmission. This mechanism is distinct from most antipsychotics, which primarily target dopamine or serotonin receptors. Sodium bicarbonate is included in the regimen to alkalinize urine, which can affect the pharmacokinetics of LY2140023 by influencing its metabolism and excretion; this combination has been studied in clinical trials to understand how urinary pH impacts drug activity and breakdown. The developer of LY2140023 is Eli Lilly. Sodium bicarbonate is a well-known buffer and is used therapeutically for metabolic acidosis and as an alkalinizing agent[1][2][3].